Doctors support BioPorto's kidney test
Danish diagnostics company BioPorto, which last week received a rejection from the US food and drug administration, FDA, now has the support of three clinical experts in the US.
BY ELIZABETH MØNSTED JOHANSEN
The FDA's rejection of BioPorto’s main asset, the NGAL test, came as a bucket of cold water in the face of the Danish diagnostics company. Over the past year, the company’s potential has been increasingly tied up with the FDA’s approval of the NGAL test, so it was not surprising that the rejection shaved off close to half of the company’s share value.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bioporto: It’s a great start to 2016
For abonnenter
BioPorto kick-starts kidney venture in Chicago
For abonnenter
